Rachael R. Schulte, MSCI, MD

Dr. Rachael Schulte is an Assistant Professor of Clinical Pediatrics in the Section of Pediatric Hematology and Oncology. She attended Indiana State University for her undergraduate degree and then received her medical degree from Vanderbilt University. She completed both a residency in Pediatrics and fellowship in Pediatric Hematology-Oncology at Vanderbilt University Medical Center. During her training, she also completed a fellowship in Pediatric Clinical Pharmacology and was awarded a Master of Science in Clinical Investigation degree from Vanderbilt University. Her clinical interests are the care of patients with leukemia, lymphoma, and vascular malformations. Her research interests are clinical trials, experimental therapeutics, clinical pharmacology, pharmacogenomics, and precision medicine.

Homan CC and 42 others [including Schulte R]. The RUNX1 Database (RUNX1db): Establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy. Haematologica 2021, online ahead of print (July 8).

Schulte RR, Choi L, Utreja N, Van Driest SL, Stein CM, Ho RH. Effect of SLCO1B1 polymorphisms on high-dose methotrexate clearance in children and young adults with leukemia and lymphoblastic lymphoma. Clin Transl Sci 2021, 14(1): 343-353.

Schulte RR, Ho RH. Organic anion transporting polypeptides: Emerging roles in cancer pharmacology. Mol Pharmacol 2019, 95(5): 490-506.

Schulte RR, Madiwale MV, Flower A, Hochberg J, Burke MJ, McNeer JL, Duvall A, Bleyer A. Levocarnitine for asparaginase-induced hepatic injury: A multi-institutional case series and review of the literature. Leuk Lymphoma 2018, 59(10): 3260-2368.

Schulte R, Jordan LC, Morad A, Naftel RP, Wellons JC, Sidonio R. Rise in late onset vitamin K deficiency bleeding in young infants due to omission or refusal of prophylaxis at birth. Ped Neur 2014, 50(6): 564-568.

Schulte RR, Linkous AG, Hallahan DE, Yazlovitskaya EY. Cytosolic phospholipase A2 as a novel molecular target for the radiosensitization of ovarian cancer. Cancer Lett 2011, 304(2): 137-143.